Biotech · Private company · Athens, GA, US
CyanVac LLC
Track this companyFree. Adds CyanVac LLC to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- COMIRNATY®Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- CVXGAPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- CVXGA (CVXGA50)Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- CVM150Phase 1 · MumpsClinicalTrials.gov · fetched Nov 12, 2026
- CVM26Phase 1 · MumpsClinicalTrials.gov · fetched Nov 12, 2026
- CVXGA1 high dosePhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- CVXGA1 low dosePhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy AdultsPHASE1 · ACTIVE_NOT_RECRUITING · started May 14, 2025ClinicalTrials.gov NCT06967181 · fetched Nov 12, 2026
- A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsPHASE2 · COMPLETED · started Dec 5, 2024ClinicalTrials.gov NCT06742281 · fetched Nov 12, 2026
- A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy AdultsPHASE2 · COMPLETED · started Sep 21, 2023ClinicalTrials.gov NCT05736835 · fetched Nov 12, 2026
- Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and AdolescentsPHASE1 · COMPLETED · started Aug 6, 2021ClinicalTrials.gov NCT04954287 · fetched Nov 12, 2026
NIH awards1
- A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)Fiscal year 2024 · $201.9KNIH RePORTER 5R21AI175677-02 · fetched Nov 12, 2026